arrow
A

Alessandra Mosca

oncology department
H指数:30
被引数:3,857

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

恩扎卢替尼在转移性激素敏感前列腺癌中的应用:国际、多中心真实世界ARON-3研究的结果

2026-01-080
OAAI
Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G

维布司妥利单抗与帕博利珠单抗联合给药于多西他赛预处理的转移性去势抵抗性前列腺癌患者:KEYNOTE-365研究G队列

2025-08-110
PREAI
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)
2024-09-070
OA
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

免疫肿瘤学联合治疗的晚期肾细胞癌和中度或低风险国际转移性肾细胞癌数据库联盟标准患者的真实世界结果: 风险组的差异有效性?

2024-02-0118
PRE
Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
2023-10-010
OA
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
2023-08-018
OA
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

接受免疫肿瘤学组合治疗晚期肾细胞癌患者的全球真实世界结果: ARON-1研究

2023-06-2721
PRE
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study

验证用于透明细胞肾细胞癌的新型三维 (3D融合) 总体采样方案以克服肿瘤内异质性: Meet-Uro 18研究

2022-04-305
OAAI
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network
2021-09-015
PRE
Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients: A multicenter randomized phase III study of the Piemonte Oncology Network
2020-09-010
OAAI